Skip to main content

Table 4 Breast cancer risk as a function of number of SLE autoantibodies, compared to the general population

From: Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection

Number of autoantibodies N No. obs. No. exp. SLE cohort SIR (95%CI) p value AA* SIR (95%CI) AA p value Non-AA^ SIR (95%CI) Non-AA p value
0–2 antibodies 1301 15 17.8 0.84 (0.47–1.39) 0.60 1.72 (0.86–3.08) 0.12 0.35 (0.10–0.90) 0.023
3+ antibodies 1130 7 17.1 0.41 (0.16–0.84) 0.010 0.65 (0.21–1.51) 0.43 0.21 (0.03–0.77) 0.010
  1. N sample size, AA African American, non-AA non-African American
  2. *N = 966 SLE patients contributing 8488 person-years
  3. ^N = 1465 SLE patients contributing 11,911 person-years